🚨 New data! In the KARDIA-2 trial, 🧬 zilebesiran—an RNAi therapeutic—cut SBP by up to 12 mmHg when added to common antihypertensives

💊. One shot, 6 months of BP control!

📉 Promising for poor adherence.

Mild AEs. #Hypertension #Cardiology #RNAi 🌍【JAMA 2025】